Cargando…

An 83‐year‐old patient with RET fusion‐positive non‐small cell lung cancer experiencing severe hepatic disorder due to selpercatinib administration

An 83‐year‐old woman with RET fusion‐positive advanced lung adenocarcinoma was administered selpercatinib 320 mg/day. Despite the shrinking of the tumour, fever, fatigue, and anorexia developed on day 17. Selpercatinib administration was interrupted. On day 21, elevated blood aspartate aminotransfer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakashima, Kazuhisa, Mitarai, Yuki, Tanaka, Seiko, Nakao, Mika, Okuno, Takae, Okimoto, Tamio, Tanabe, Ryo, Yanagawa, Takashi, Tsubata, Yukari, Isobe, Takeshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2023
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083545/ https://www.ncbi.nlm.nih.gov/pubmed/37051304 http://dx.doi.org/10.1002/rcr2.1136

Ejemplares similares

Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment
por: Okuno, Takae, et al.
Publicado: (2022)

Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment
por: Okuno, Takae, et al.
Publicado: (2022)

Disseminated Nocardiosis Initially Manifesting as Visual Field Defects
por: Okimoto, Tamio, et al.
Publicado: (2018)

An endobronchial hamartoma observed using narrow band imaging under saline injection: A case report
por: Kobayashi, Misato, et al.
Publicado: (2022)

A Retrospective Study of Pneumococcal Pneumonia in Hospitalized Patients Aged ≥65 Years in Izumo, Japan: 2010 to 2014
por: Hamaguchi, Megumi, et al.
Publicado: (2023)

Reproducible abscopal effect in a patient with lung cancer who underwent whole‐brain irradiation and atezolizumab administration
por: Hotta, Takamasa, et al.
Publicado: (2021)

Successful rechallenge with ceritinib after leukocytoclastic vasculitis during ceritinib treatment for non-small cell lung cancer harboring the EML4-ALK fusion protein
por: Okimoto, Tamio, et al.
Publicado: (2018)

Varicella-zoster Virus Related Pulmonary Granulomas in Which Varicella-zoster Virus DNA Was Demonstrated in a Thoracoscopic Lung Biopsy Specimen
por: Isobe, Takeshi, et al.
Publicado: (2019)

Comparative Analysis of the Attitudes toward Palliative Care between Medical Oncologists and Pulmonologists
por: Okimoto, Tamio, et al.
Publicado: (2021)

Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
por: Gouda, Mohamed A., et al.
Publicado: (2023)

Immune‐related adverse events in hepatitis treated with thiopurine‐based immunosuppressants: A case report
por: Kawakado, Keita, et al.
Publicado: (2023)

IgA Nephropathy that Developed as an Immune-related Adverse Event of Pembrolizumab Complicated with Interstitial Nephritis
por: Mitarai, Yuki, et al.
Publicado: (2021)

A Low Crizotinib Concentration in the Cerebrospinal Fluid Causes Ineffective Treatment of Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer with Carcinomatous Meningitis
por: Okimoto, Tamio, et al.
Publicado: (2018)

Clinical Activity of Selpercatinib in RET Mutant Pheochromocytoma-Case Reports
por: Konda, Bhavana, et al.
Publicado: (2021)

Acute Interstitial Lung Disease Induced by Rechallenge with Ceritinib
por: Hotta, Takamasa, et al.
Publicado: (2019)

Prospective clinical trial evaluating vulnerability and chemotherapy risk using geriatric assessment tools in older patients with lung cancer
por: Tsubata, Yukari, et al.
Publicado: (2019)

Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma
por: Schrenk, Karin G., et al.
Publicado: (2022)

Pleuroparenchymal fibroelastosis after haematopoietic stem cell transplantation without graft‐versus‐host disease findings
por: Okimoto, Tamio, et al.
Publicado: (2018)

Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA
por: Della Corte, C.M., et al.
Publicado: (2021)

Selpercatinib Treatment of RET-Mutated Thyroid Cancers Is Associated With Gastrointestinal Adverse Effects
por: Tsang, Venessa, et al.
Publicado: (2022)

Drug-Induced Eosinophilic Pneumonia as an Adverse Event of Abemaciclib
por: Mitarai, Yuki, et al.
Publicado: (2022)

Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring RET Gene Alterations
por: Ortiz, Michael V., et al.
Publicado: (2020)

Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET Fusion–Positive Breast Cancer
por: Watanabe, Satomi, et al.
Publicado: (2021)

Exogenous lipoid pneumonia caused by herbicide inhalation
por: Hotta, Takamasa, et al.
Publicado: (2016)

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations
por: Subbiah, V., et al.
Publicado: (2020)

Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer
por: Tong, Xuexia, et al.
Publicado: (2019)

Durable Disease Control by RET Inhibitor Selpercatinib in a Heavily Pre-Treated RET Fusion-Positive Papillary Thyroid Cancer
por: Yokota, Tomoya
Publicado: (2022)

Comparison of Ultra-Magnifying Endocytoscopic and Hematoxylin-Eosin-Stained Images of Lung Specimens
por: Kobayashi, Misato, et al.
Publicado: (2023)

Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma
por: Werner, Rudolf A., et al.
Publicado: (2022)

D898_E901 RET Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms
por: Porcelli, Tommaso, et al.
Publicado: (2023)

Clinical Management of Asthma by Respiratory Specialists versus General Practitioners: Questionnaire Survey Results Over 6 Years
por: Hamaguchi, Megumi, et al.
Publicado: (2021)

Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells
por: Okimoto, Tamio, et al.
Publicado: (2020)

Use of saline to evaluate a cavity due to Mycobacterium kansasii infection during ultrathin bronchoscopy and endobronchial ultrasonography
por: Hamaguchi, Megumi, et al.
Publicado: (2021)

The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib
por: Shen, Tao, et al.
Publicado: (2021)

High serum C-reactive protein levels predict survival in patients with treated advanced lung adenocarcinoma
por: Hotta, Takamasa, et al.
Publicado: (2021)

Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases
por: Andreev-Drakhlin, Alexander, et al.
Publicado: (2020)

SUN-LB75 The Anti-Tumor Activity of the Selective Ret Inhibitor Selpercatinib (LOXO-292) in Medullary Thyroid Cancer Is Independent of the Specific RET Mutation
por: Cabanillas, Maria E, et al.
Publicado: (2020)

Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial
por: Subbiah, Vivek, et al.
Publicado: (2021)

Salvage Therapy With Selpercatinib for RET-Rearranged NSCLC With Pralsetinib-Related Pneumonitis and Leptomeningeal Disease: A Case Report
por: d'Arienzo, Paolo D., et al.
Publicado: (2023)

Selpercatinib: First Approval
por: Markham, Anthony
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2o6l4blk734a8e38onfqs9db1f